NYC-based Investment firm Deerfield Management Company, L.P. closed the Deerfield Healthcare Innovations Fund ll, L.P., at $840m.
The Healthcare Innovations Fund II will invest in advancements in science that may lead to important therapeutic interventions and back new technologies and infrastructure to improve the way healthcare is delivered to patients. It will collaborate with more than 15 leading academic institutions to seed novel scientific research.
The fund also has access to innovative medtech incubators created in partnership with two medical device industry leaders. The Cure, the recently announced innovation campus located at 345 Park Avenue South, will become the central location of Deerfield where much of the work of the Healthcare Innovation Fund II will take place. Many of the early-stage companies will utilize the Cure’s wet and dry labs, engineering, computing and shared resource spaces. The companies will also benefit from on-site programming, including the Fellows Program, Break into the Boardroom and Women in Science. Newly curated programs to be featured involve the “Cure Lounge,” a thought leadership and executive club, and other educational and certification initiatives.
Led by James E. Flynn, managing partner, Deerfield Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy.
Today, Deerfield has more than 130 experienced healthcare-focused professionals with specialized knowledge in medicine, life sciences, drug and medical device development, healthcare markets, public policy, value-based care, financial instruments, tax, accounting, operations, corporate strategy, market access research, marketing, biostatistics and sector dynamics, all of which can be leveraged by its partners.
FinSMEs
06/04/2020